Eisai Inc., a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., will expand its Research Triangle Park facility, creating 59 new jobs and investing $90 million over the next three years. The company plans to add an additional 25 jobs by 2011. The announcement was made possible in part by a $150,000 One North Carolina Fund grant.

Eisai Inc. is headquartered in Teaneck, New Jersey and maintains its only U.S. pharmaceutical production and formulation research and development operations in Research Triangle Park. The new jobs will include quality control analysts, manufacturing and packaging operators, chemists, engineers and technicians.

"We are excited to expand our operations in RTP, where our high compliance standards will be instrumental for regulatory approvals and production of our first anticipated oncology product," said Lou Arp, vice president of production operations at Eisai Inc. "Constructing the new facility at our current location allows for seamless integration between our production and research and development departments as well as access to North Carolina’s strong talent pool."

The One North Carolina Fund assists the state in industry recruitment and expansion by providing financial assistance through local governments to attract business projects that will stimulate economic activity and create new jobs in the state. One North Carolina Fund grants require and are contingent upon a local match. Through the use of this Fund, more than 18,000 jobs and $2.5 billion in investment have been created since 2001.